Study Tests Potential Herpes Vaccine

Article

A study underway at the University of Alabama at Birmingham (UAB) aims to determine whether an experimental vaccine is safe and effective in preventing genital herpes in young women.

 

The study marks the final phase of testing for the candidate vaccine, called HERPEVAC, developed by GlaxoSmithKline (GSK).

 

"If proven effective it will be the first vaccine for a sexually transmitted disease," says Edward Hook, MD, professor of medicine.

 

Nationally, 40 sites are participating in the study, directed by the National Institute of Allergy and Infectious Diseases and GSK. In total, sites will enroll 7,500 women between the ages of 18 and 30 who do not have oral or genital herpes. UAB will enroll 500 volunteers.

 

Source: UAB

 

Recent Videos
mpox   (Adobe Stock 924156809 by Andreas Prott)
Meet Alexander Sundermann, DrPH, CIC, FAPIC.
Veterinary Infection Prevention
Andreea Capilna, MD, PhD
Meet the Infection Control Today Editorial Advisory Board Members: Priya Pandya-Orozco, DNP, MSN, RN, PHN, CIC.
Meet Infection Control Today's Editorial Board Member: Tommy Davis, PhD, ACHE, APIC, BLS
Fungal Disease Awareness Week
Meet Shannon Simmons, DHSc, MPH, CIC.
Meet Matthew Pullen, MD.
Related Content